Log In
Print this Print this

Impavido, miltefosine

  Manage Alerts
Collapse Summary General Information
Company Knight Therapeutics Inc.
DescriptionAlkylphosphocholine analog that inhibits cholinephosphate cytidyltransferase
Molecular Target Cholinephosphate cytidyltransferase
Mechanism of ActionAntifungal agent
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationLeishmaniasis
Indication DetailsTreat cutaneous leishmaniasis; Treat Indian visceral leishmaniasis (VL); Treat leishmaniasis; Treat mucocutaneous leishmaniasis; Treat recurrent visceral leishmaniasis (VL) in HIV-infected patients who had failed 1-9 prior courses of standard therapy; Treat visceral and cutaneous leishmaniasis; Treat visceral leishmaniasis (VL)
Regulatory Designation U.S. - Fast Track (Treat leishmaniasis);
U.S. - Orphan Drug (Treat leishmaniasis);
U.S. - Priority Review (Treat leishmaniasis);
U.S. - Priority Review (Treat cutaneous leishmaniasis);
U.S. - Priority Review (Treat visceral leishmaniasis (VL))
Partner Roche; Zydus Cadila Group

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today